|
Dr. Ryan Million is a Principal and founding member and manager of Trinity’s New York City office. Dr. Million’s practice at Trinity focuses on licensing and acquisition due diligence, revenue forecasting, marketing data analysis and business strategy for pharmaceutical companies in several therapeutic areas. In the area of oncology L&A, Dr. Million’s efforts have resulted in the successful licensing of two oncology drugs for one of Trinity’s core clients. In addition, Dr. Million brings experience from engeneOS, Inc., a venture-backed biotechnology start-up company in Waltham, MA, where he was a member of the business development team, delivering strategy, competitive intelligence and technology due diligence. Dr. Million completed his doctorate training in the Genetics Department at Harvard University publishing several peer-reviewed scientific papers on the ABL oncogene (target of Novartis’s Gleevec) and a mouse model of chronic myeloid leukemia. Dr. Million attended the University of California, San Diego where he earned a B.S. in Chemistry/Biochemistry, graduating cum laude and Phi Beta Kappa. | 